Clin Transl Oncol (2017) 19:1117–1124 DOI 10.1007/s12094-017-1647-9 RESEARCH AR TIC L E Efﬁcacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer 1,2 1,2 1,2 1,2 1,2 2,3 • • • • • • K. Zhou F. Wen P. Zhang J. Zhou H. Chen H. Zheng 1,2 1,2 Y. Yang Q. Li Received: 23 November 2016 / Accepted: 13 March 2017 / Published online: 28 March 2017 Federacio ´ n de Sociedades Espan ˜ olas de Oncologı ´a (FESEO) 2017 Abstract cost-effective ratio was $18,223.75/QALY for second-line Purpose Second-line chemotherapy has been shown to chemotherapy versus BSC, which was below the threshold beneﬁt patients with advanced gastric cancer (AGC), of 39 the per capita GDP of China, $23,970.00. extending the overall survival (OS) and progression-free Conclusion Second-line chemotherapy was an optimal survival (PFS). This study aimed to assess the efﬁcacy and strategy for elderly AGC patients in China from the efﬁ- cost-effectiveness of second-line treatment for elderly cacy and cost-effectiveness perspective. patients with AGC. Methods Medical records and follow-up information of Keywords Cost-effectiveness Advanced gastric cancer elderly patients (C70 years) with AGC who received second- Elderly Second-line chemotherapy line chemotherapy were collected. A Markov
Clinical and Translational Oncology – Springer Journals
Published: Mar 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera